{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "733ff7ae8b05564a3bdfa2fec81a5e12",
    "title": "Jefferies",
    "source_uri": "2025-08-29/FY25 - Be StillFY25 - Be Still_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:40:41.413392",
      "extracted_at": "2025-10-27T00:40:41.413401"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 16,
        "successful_pages": 16,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 7,
          "reduction_ratio": 0.09834727410665411
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "75c54e24aaa31525",
      "text": "Australia | Biotechnology",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2beb9550eca5a417",
      "text": "IMM is still on track - IMM's eftilagimod is progressing well compared to peers with regards to metastatic 1L NSCLC & 1L HNSCC: 1) efti/pembro has the highest Objective Response Rate in certain metastatic 1L NSCLC & 1L HNSCC; and 2) efti/pembro has the highest median Overall Survival compared to other potential drug therapies in 1L NSCLC & 1L HNSCC. FY25 was basically in line with our forecasts.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d8d675e122d78465",
      "text": "**IMM's FY25 was basically in line with our forecasts.** In FY25, eftilagimod alfa (efti), advanced into a global registrational Phase 3 trial in non-small cell lung cancer (TACTI-004/KEYNOTE-F91), with the first patient dosed in March 2025.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "67a2b9743b42825a",
      "text": "**Eftilagimod/pembrolizumab has the highest Objective Response Rate in certain metastatic** **1st Line Non-Small Cell Lung Cancer (1L NSCLC) patients when compared to other drug** **combinations.** We note Merck's (MRK US, Buy, PT US&#36;141) pembrolizumab (Keytruda, US &#36;29.5Bn in FY24 revenue) patent ends in 2028. IMM previously stated eftilagimod plus pembrolizumab (efti/pembro) could extend this to 2036. We have analysed relevant competing trials of therapeutic agents being trialed in combination with pembro that could also act to extend pembro's opportunity in 1L NSCLC. We believe IMM has as its primary target market patients with a low Tumor Proportion Score of 1-49%, c37% of the total advanced NSCLC market.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5cfdd1669efb861f",
      "text": "**Efti/pembro has the highest median Overall Survival (mOS) when compared to other** **potential drug therapies in 1L NSCLC.** We note: 1) In TPS&gt;1 patients, efti/pembro basically leads to at least two times higher mOS compared to pembrolizumab monotherapy; 2) When we compare the Phase 2 efti/pembro trials to other agents that have completed Phase 3, efti/pembro gives the best mOS - 35.5 months in 1L NSCLC.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "91a9790e18c26930",
      "text": "**Also, efti/pembro has the highest Objective Response Rate in certain 1st Line Head** **and Neck Squamous Cell Cancer (1L HNSCC) patients when compared to other drug** **combinations.** Should the efti/pembro trials succeed, then efti/pembro could treat 1L HNSCC patients with a Combined Positive Score &lt;1 under a new treatment regimen, c20% of the total 1L HNSCC market.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5799ab34c42aed83",
      "text": "**Also, efti/pembro has the highest median Overall Survival (mOS) when compared to other** **potential drug therapies in 1L HNSCC.** We note: 1) In CPS&lt;1 patients, efti/pembro basically leads to at least-two times higher median overall survival compared to pembrolizumab monotherapy; 2) When we compare the Phase 2B efti/pembro trials to other agents that have completed Phase 3, we note efti/pembro gives the best mOS - 17.6 months in 1L HNSCC.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "bc8ef0a494a56545",
      "text": "**Changes to forecasts.** Changes to forecasts include: 1) updating FY26E+ COGS in line with FY25; and 4) Updating other cost lines for FY26E+ in line with FY25. we make no changes to efti/MM efti revenue forecasts.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "02a8069d52d6ffcd",
      "text": "**PT unchanged at A&#36;2.10.** We calculate the total revenue protected for pembrolizumab from combination therapy with eftilagimod could be cUS&#36;5Bn per annum.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6f6f969539e506bb",
      "text": "FY (Jun)2025A2026E2027E2028ERev. (MM)5.04.34.0418.3EBITDA (MM)(62.8)(80.9)(101.7)159.9Net Profit(61.4)(81.0)(102.4)108.8EPS(0.04)(0.05)(0.05)0.05",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e99ae62ba3c8dbfe",
      "text": "Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 11-16 of this report. * Jefferies (Australia) Pty Ltd",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3296bbf8f5bd0dff",
      "text": "Equity ResearchAugust 29, 2025",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d4e25e060ee3007b",
      "text": "RATINGBUYPRICEAUD0.25*PRICE TARGET | % TO PTAUD2.10|+757%52W HIGH-LOWAUD0.42-AUD0.22FLOAT (%)| ADV MM (USD)85.3%|0.62MARKET CAPAUD407.8M|&#36;266.1MTICKERIMM AU",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "741be7110859bfaa",
      "text": "*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1245a5b251c0e110",
      "text": "FY (Jun)CHANGE TO JEFeJEF vs CONS2026 20272026 2027REVNANA NAEPSNANA NA",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cb52e7ec6123876d",
      "text": "2026 (AUD)1Half2HalfFYEPS(0.03)(0.03)(0.05)PREV",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "794866e9fefa302c",
      "text": "Figure 1 -Immutep - risk-weighted valuation of portfolio",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "81bf9d9bfeb11d3e",
      "text": "Source: Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ee92879bd27620a3",
      "text": "Figure 2 -Immutep - revenue by indication (A $m)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "98997c6e52362861",
      "text": "Source: Jefferies estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4e75a19c543884ae",
      "text": "**Vanessa Thomson * | Equity Analyst**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1834e43a93f02351",
      "text": "Investment Thesis / Where We DifferIMM's eftilagimod alpha (efti) is a soluble LAG- 3 protein binding to a subset of MHC class II molecules, thus mediating antigen- presenting cell (APC) and CD8 T- cell activation. Such stimulation of the dendritic cell network and resulting T- cell recruitment may lead to stronger anti- tumor responses in combination with pembrolizumab than observed with pembrolizumab alone. IMM is not without risks, but there is the chance for meaningful upside should its products be approved. Clearly, IMM's major hurdles include further positive clinical trial results, regulatory approval, and further manufacturing development.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3f3c410b4a1d3f43",
      "text": "Base Case, AUD2.1, +757%Our base case price target uses our risk- weighted valuations for the near- term valuations in the IMM pipeline. These are: 1) Treatment of advanced breast cancer; 2) Treatment of Non- Small Cell Lung Cancer; and 3) Treatment of Head and Neck Squamous Cell Carcinoma.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1bc3e75254ee7ea8",
      "text": "Upside Scenario, AUD4.81, +1,863%Our upside case price target is a non- risk weighted valuation for our valuation of IMM's base- case opportunities.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "cd7abc1beb151b7e",
      "text": "Downside Scenario, AUD0.05,- 80%Our downside case assumes all clinical trials fail. Hence, the stock would likely trade at its cash backing, which is our downside case.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dee265a09a2467c8",
      "text": "Pricing is a major issue. Device and drug pricing has always been tied to several social considerations of ESG, such as customer relationships, demographic changes, and social awareness, and it has continually been among the main measures of reputation and regulatory risk.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "fdc3de39994d9988",
      "text": "1) No targets for reducing its emissions. \n2) Sustainability targets have not been set by the company.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "cabb5c98fe74331a",
      "text": "1) How is IMM expanding its ESG framework in line with its ongoing need for funds to continue with its R&D pipeline? \n2) How is IMM ensuring safe disposal of clinical trial by products? \n3) How is IMM ensuring safety of clinical trial participants?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c9ceaf04df74be55",
      "text": "CatalystsIn terms of catalysts, IMM's product candidates use its technologies in the treatment of breast cancer as well as non- small- cell lung cancer and head and neck squamous cell carcinoma. Success in any of these clinical trials would lead to a positive re- rating of IMM's share price, in our view.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ce33d26967f0dac9",
      "text": "(Note: To commemorate the recent passing of co- founder Brian Wilson, we will be using Beach Boys' songs for our note titles in this reporting season.)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1cc4197ce1eea4bc",
      "text": "Figure 3 -Immutep - Expanded Summary Table (ASm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cae182895aacbf17",
      "text": "Year-end 30 June (ASm)FY24AFY25AFY26EFY27EFY28ERevenue4544418EBITDA(44)(63)(81)(102)160EBIT(47)(65)(83)(104)153Normalised NPAT(43)(61)(81)(102)109JEF NPAT/consensus (%)nananananaFully diluted norm EPS(0.04)(0.04)(0.05)(0.05)0.05EPS growth on pcp (%)(20.4)18.722.94.5(195.0)EV/EBITDA (x) (JEF)(4.4)(4.6)(4.6)(4.7)2.3EV/EBIT (x) (JEF)(4.2)(4.5)(4.5)(4.6)2.4FD normalised P/E (x) (JEF)(8.3)(5.8)(5.0)(5.1)4.8Dividend yield (%)0.00.00.00.00.00ROE(22.5)(42.8)(71.9)(85.1)47.5Net debt/equity (%)net cashnet cashnet cashnet cashnet cash",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "3fd0990394b91f5f",
      "text": "Source: Company data, Jefferies estimates, IRESS",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "da33a96479c42746",
      "text": "IMM's etfialgmod is proessing well compared to peers with regards to metastatic 1L NSCLC & 1L HNSCC: 1) efti/pembro has the highest Objective Response Rate in certain metastatic 1L NSCLC & 1L HNSCC; and 2) efti/pembro has the highest median Overall Survival compared to other potential drug therapies in 1L NSCLC & 1L HNSCC. FY25 was basically in line with our forecasts.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2393f4c1f8234f23",
      "text": "Changes to forecasts include: 1) updating FY26E+ COGS in line with FY25; and 4) Updating other cost lines for FY26E+ in line with FY25. we make no changes to our IMM efti revenue forecasts.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5600e06d228d9d14",
      "text": "Figure 4 -Immutep - changes to forecasts (ASm)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "df80df5eda9d10a7",
      "text": "FY25AFY26EFY27EFY28EPrevRevDiff (%)PrevRevDiff (%)PrevRevDiff (% )PrevRevDiff (%)Sales revenue (ASm)0.00.00.00.0(80.9)(97.7)(101.7)0.00.0415.3415.30.0EBITDA (ASm)(59.6)(62.8)(78.1)(81.0)(83.3)(100.1)(103.9)0.00.0157.9152.6(3.2)EBIT (ASm)(63.2)(65.2)(80.6)(83.3)(81.0)(99.7)(102.4)0.00.0111.6108.8(2.5)NPAT (ASm)(58.2)(61.4)(79.7)(81.0)(5.2)(5.3)(5.4)0.00.05.45.1(4.6)EPS (c)(4.0)(4.2)(5.1)(5.2)(5.2)(5.3)(5.4)0.00.00.00.00.6DPS (c)0.00.00.00.00.000.00.00.00.70.00.00.0Net op cashflow (ASm)(56.6)(62.0)(78.2)(79.6)(98.1)(100.9)(117.2)114.40.00.00.00.0",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cc8dc71f13898387",
      "text": "Source: Company data, Jefferies estimates",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e679c74747770568",
      "text": "IMM's eftialgmod alpha (eftialgmod, efti) is a prospective cancer drug that continues to progress through clinical trials. It is a version of the LAG- 3 immune checkpoint and acts as an Antigen Presenting Cell (APC) Activator, effectively increasing the number of relevant immune cells and potentially leading to the destruction of tumours by immune cells when used in combination with conventional immune checkpoint inhibitors like pembrolizumab. More immune cells may lead to increased cancer destruction - eftialgmod drives the proliferation of cells within the adaptive immune system (CD8 and CD4 T- cells).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "beb727050adf4d02",
      "text": "Figure 5-Immutep-R&D pipeline As at June 2025",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "876410ea0fef66d7",
      "text": "ProgramIndication(s)PreclinicalPhase IPhase IIPhase IIIENDOXID1L Non-Small Cell Lung Cancer (NSCLC)TACTI-004 | Erfi + Pembrolizumab + Chemo *1L Head &amp;amp; Neck Squamous Cell Carcinoma (HNSCC)TACTI-003 | Erfi + Pembrolizumab *1L NSCLC, 2L HNSCC, PD-X Refractory 2L NSCLCTACTI-002 | Erfi + Pembrolizumab *1L Non-Squamous NSCLCINSIGHT-003 | Erfi + Pembrolizumab + Chemo $Urothelial CancerINSIGHT-005 | Erfi + Avelumab $ *Soft Tissue SarcomaETISARC-NEO | Erfi + Pembrolizumab $HR+/HER2-Metastatic Breast Cancer &amp;amp; TNBCAIPAC-003 | Erfi + PaclitaxelMetastatic Breast Cancer &amp;amp; Solid TumorsErfi + Paclitaxel and Erfi + Pembrolizumab #Anti-LAG-3 Small MoleculeUndisclosedLAG525Anti-LAG-3Anti-LAG-3Anti-LAG-3Anti-LAGAnti-LAGAnti-LAGAnti-AGAnti-LAGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAGAnti-AGAntibodyAnti-LAG",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7b01a538c9434d74",
      "text": "We believe IMM has as its primary target market patients with a low Tumor Proportion Score (TPS) of 1- 49% (a 'cold' tumour), c37% of the total 1L NSCLC market.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "0a76e448a6d3ac95",
      "text": "The Tumor Proportion Score in non- small cell lung cancer is defined as the percentage of viable tumor cells showing partial or complete membrane staining for PD- L1 (programmed death- ligand 1) by immunohistochemistry, relative to all viable tumor cells present in the sample. The TPS is expressed as a percentage, ranging from 0% (no tumor cells stained) to 100% (all tumor cells stained).",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "49d5ee3d1344fde1",
      "text": "- Competing drugs that saw comparable ORR to eftilagimod in IMM's TACTI-002 trial are only recruiting patients with TPS>50%, and so are not targeting the same primary market as eftilagimod and pembrolizumab, which is likely to be TPS1-49%. These competing trials are TROPION-Lung08, MK-3475-D46 and MK-2870-007.- The Objective Response Rate (ORR) is highest for pembrolizumab and eftilagimod in TPS 1-49% in early stage trials when compared to peers.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "cd122f130470789b",
      "text": "That said, these trials are likely to read out Phase 3 results before IMM's upcoming Phase 3 TACTI- 004 study.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "ab0e216c6c185ea8",
      "text": "Figure 6 - Trials in Combination with pembrolizumab in metastatic 1st line non-small cell lung cancer (1L NSCLC)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6ad97e24a2e2a922",
      "text": "Combination:PhaseTypeNo. of patientsStatusCompany/ins titution initiating trialEstimated Primary Completi on datePhase 1/2 Objective Response Rate, Progression Free Survivalwith Metastatic 1L pembr NSCLC1Datopotamab Deruxtecan (TROPION-Lung08)3Randomized, Open-label740RecruitingDaiichi SankyoJun-262Sacituzumab Goviecan (MK-3475-D46 trial)3Open-label, Multicenter, Randomized, Active-Comparators-Controlled Randomized, Open-label614RecruitingGilead SciencesJan-273MK-2870 (MK-2870-007 trial)3Randomized, Open-label614RecruitingMerck Sharp &amp;amp; Dohme LLCJan-284Eftilagimod (TACTI-004, KEYNOTE PNC91)3Randomised, Double-blind, Multicentre750RecruitingImmutepJun-285Lenvatinib (KEYNOTE 495)2Randomized, Open-label106Active, not recruitingMerck Sharp &amp;amp; Dohme LLCJun-256Quavotinimab (anti-2 CTLA-4) (KEYNOTE 495)2Randomized, Open-label106Active, not recruitingMerck Sharp &amp;amp; Dohme LLCJun-25",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b48cb347b9f658db",
      "text": "Source: Company data, PubMed",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f9051d239a959035",
      "text": "We have analysed the combination of eftilagimod/pembrolizumab combination against other agents being developed for 1L NSCLC. We note:",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "23dbfed880594809",
      "text": "- In TPS>1 patients, a combination of pembrolizumab plus eftilagimod basically leads to at least two times higher median overall survival compared to pembrolizumab mono therapy",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "643ecc609a763654",
      "text": "- When we compare the Phase 2 combination of pembrolizumab plus efaligamod trials to other agents that have completed Phase 3, we note the combo of pembrolizumab plus efaligamod gives the best median overall survival – 35.5 months in 1L NSCLC",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a1b144b52515990e",
      "text": "- That said, these results were in open-label trials. These results must be repeated in a randomised Phase 3 trial, namely the TACTI-004 trial.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c3ec4934204a4d0d",
      "text": "- We understand that the TACTI-004 clinical trial will be stratified, with distinct results (and p values) to be generated for patients in the TPS 1-49% subgroup, as well as the TPS>50% subgroup.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8d9cd979ae054838",
      "text": "Figure 7 - Efti/Keytruda combination and monotherapy vs. other agents being developed for 1L NSCLC",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "aa8e62f4fec1989f",
      "text": "Indication: 1L NSCLCTPS statusPhaseTypeNo. of ptsStatusCompany initiating trialProgression Free Survival (m)Median Overall survival (m)pembrolizumab plus efaligamod (TACTI-002)TPS&amp;gt;12Open Label, Randomized58Active, not recruitingImmupet11.235.5ivonesimab (HARMONI-2/AK112-303)TPS&amp;gt;13Randomised, Double-blind, Multicentre398Active, not recruitingAkeso Bio11.1napembrolizumab plus pemetrexed and platinum (KEYNOTE-189)TPS&amp;gt;13Randomised, Double-blind, Multicentre410CompletedMerck9.223.3nivolumab plus ipilimumab (CheckMate-227)TPS&amp;gt;13Randomised, Double-blind, Multicentre396CompletedBMSna17.1pembrolizumab monotherapy (KEYNOTE-042)TPS&amp;gt;13Randomised, Double-blind, Multicentre637CompletedMerck5.416.4nivolumab plus ipilimumab plus chemotherapy (CheckMate-9LA)TPS&amp;gt;13Randomised, Double-blind, Multicentre204CompletedBMSna15.8paclitaxel plus pemetrexed (KEYNOTE-042)TPS&amp;gt;13Randomised, Double-blind, Multicentre637CompletedMerck6.612.1",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f9135f4ee35fa88e",
      "text": "Source: PubMed, Company data",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "57c7ec549f3a40db",
      "text": "We have also analysed relevant competing trials of therapeutic agents in combination with pembrolizumab in 1L NHSCC that could also act to extend pembrolizumab's opportunity in 1L NHSCC.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "099c6e09a7742219",
      "text": "We believe IMM has as its primary target market patients with a low combined positive score of",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "19e99e2e0f70a8ce",
      "text": "Figure 8 - Trials in combination with pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "456537dc71a0134e",
      "text": "Comb with pembro.Indication: 1L HNSCCPhaseTypeNo. of ptsStatusCompany/institution initiating trialEstimated Primary Compa datePhase 1/2 Objective Response Rate, Progression Free Survival1Petosemtamab2&amp;amp;3Randomized500RecruitingMerus NVJan-281L: Overall ORR: 63%, ORR in CPS&amp;lt;1: na, ORR in CPS 1-19: 47%, ORR in CPS&amp;gt;20: 73%. mPFS 9 months2Zanzalintinib (STELLAR-305)2&amp;amp;3Randomized, Double-Blind, Controlled500RecruitingExelixisAug-28Recruiting in 1L for CPS ≥1. Previous 2L: Overall ORR: 54%, Median OS in CPS&amp;lt;20: 15 months, median OS in CPS&amp;gt;20: 33 months. Overall PFS: 14.6 months Recruiting for CPS&amp;gt;203INBRX-106 (HexAgon HN)2&amp;amp;3Randomized410RecruitingInhibixMay-291L: Overall ORR: 30%. 1L: ORR in CPS&amp;lt;1: 36% (mOS 17.6m), ORR in CPS 1-19: 35%, ORR in CPS&amp;gt;20: 31%, ORR in CPS&amp;gt;1: 33%.4Eftaligimod (TACTI-003)2BOpen Label, Randomized171Active, not recruitingImmutepMar-25Recruiting for CPS≥15Ipatasertib2Randomized52Active, not recruitingNational Cancer InstituteJul-252L: Overall ORR in CPS&amp;gt;25: 16.2%. Median OS in CPS&amp;gt;25: 7.1 months6Danvatrisen2Open Label, Randomized81RecruitingFlamingo Therapeutics NVMay-267Brentuximab vedotin2Open-label, randomized140RecruitingSeagenSep-26na8Tadalafil2Open label6RecruitingUniversity of California, San DiegoMar-29na9Galectin-3 Inhibitor (GB1211)2Randomized, Double-Blind, Placebo Controlled Open-Label, Randomized92RecruitingProvidence Health &amp;amp; ServicesFeb-30na10Ramucirumab272RecruitingWashington University Apr-31 School of Medicine1L: Overall ORR: 64%, ORR in CPS&amp;lt;20: 64%, ORR in CPS&amp;gt;20: 60%. Overall PFS: 2.1 months",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "f648a4028d5e20a5",
      "text": "Source: clinicaltrials.gov, company data",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2ada5d7cbab20edc",
      "text": "We have analysed the combination of eftaligimod/pembrolizumab combination against other agents being developed for 1L HNSCC. We note:",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "016e782493d374db",
      "text": "In CPS&amp;lt;1 patients, a combination of pembrolizumab plus eftaligimod basically leads to at least two times higher median overall survival compared to pembrolizumab monotherapy. When we compare the Phase 2B combination of pembrolizumab plus eftaligimod trials to other agents that have completed Phase 3, we note the combo of pembrolizumab plus eftaligimod gives the best median overall survival - 17.6 months in 1L HNSCC That said, these results were in open label trials. These results must be repeated in a randomised Phase 3 trial.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e9949eedf31a7ff8",
      "text": "- We hope that any Phase 3 clinical trial in HNSCC will be stratified, with distinct results (and p values) to be generated for patients in the CPS1 subgroup.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "a057e06e2e470dc9",
      "text": "Figure 9 - Efti/Keytruda combination and monotherapy vs. other agents being developed for 1L HNSCC",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "af7eb0bc4e5b6c80",
      "text": "Indication: 1L HNSCCCPS statusPhaseTypeNo. of ptsStatusCompany initiating trialObjective Response Rate, Progression Free SurvivalMedian Overall survival (m)pembrolizumab + eftilagimod (TACTI-003)CPS&amp;lt;12Open Label, Randomized31CompletedImmutep1L: ORR in CPS&amp;lt;1: 36%17.6pembrolizumab monotherapy (KN-048) cetuximab + chemotherapy (KN-048)CPS&amp;lt;13Open Label / Randomized43CompletedMerck1L: ORR in CPS&amp;lt;1: 4.5%7.9pembrolizumab + chemotherapy (KN-048)CPS&amp;lt;13Open Label / Randomized43CompletedMerck1L: ORR in CPS&amp;lt;1: 31%10.7lvosencimab monotherapy (AK117-201)CPS&amp;gt;12Open Label, Randomized10Active, not completedAkeso Bio1L: ORR in CPS&amp;lt;1: 40%11.3lvosencimab plus ligufalimab (AK117-201)CPS&amp;gt;12Open Label, Randomized20Active, not completedAkeso Bio1L: ORR in CPS&amp;gt;1 is 30%. mPFS is 5.0mna",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "571380358aaed413",
      "text": "Source: Company data, PubMed",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "553441ff2541f89a",
      "text": "We note that in the more advanced trials, the competing Phase 3 trials are being performed in CPS \\(\\geq 1\\) , so not competing with efti/pembro.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6538b7154cd8b8c2",
      "text": "We note pembrolizumab's (US\\$29.5Bn in FY24 revenue) patent ends in 2028. IMM previously stated eftilagimod plus pembrolizumab could effectively extend this to 2036. In the following figure, we have calculated annual revenue protected for pembrolizumab from combination therapy with eftilagimod (assuming patent protection for a combination of pembrolizumab and eftilagimod from 2028 to 2036) for both 1L NSCLC and 1L HNSCC. We calculate that the total revenue protected per annum for pembrolizumab from combination therapy with eftilagimod could be US\\$5.0Bn, should this combination be successful.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "5e840e227ebbce44",
      "text": "Figure 10 - Calculating annual revenue protected for Keytruda from combination therapy with Eftilagimod",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "85375eb6ebad1c77",
      "text": "Calculating annual revenue protected for Keytruda from combination therapy with Eftilagimod (US$Bn) (assuming patent protection for a combination of Keytruda &amp;amp; Efti. from 2028 to 2036)Keytruda revenue in FY2429.51L NSCLC as a percentage of total volume of use of Keytruda40%Within 1L NSCLC, TPS 1-49% as a percentage of total Ca37%Hence, revenue protected per annum for Keytruda from combo. Rx with Efti4.41L HNSCC as a percentage of total volume of use of Keytruda10%Within HNSCC, CPS &amp;lt;1 as a percentage of total Ca20%Hence, revenue protected per annum for Keytruda from combo. Rx with Efti0.6From this, total revenue protected per annum for Keytruda from combo. Rx with Efti5.0",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d012a44a95b37578",
      "text": "Source: Company data, Jefferies estimates",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0c302c809c21850c",
      "text": "We enclose IMM's Income statement below.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "8a3eab6359c6a823",
      "text": "Figure 11-Immutep-income statement (A\\$m)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "c7bb29e693cb5d13",
      "text": "Income Statement (A$m)1H24A2H24AFY24A1H25A2H25AFY25A1H25 on 1H24 (%)2H25 on 2H24 (%)FY25 on FY24 (%)Sales revenue0.00.00.00.00.000.0Other revenue2.11.73.83.11.95.049.19.531.3COGS0.00.00.00.00.000.0Other expenses(24.1)(24.2)(48.3)(28.1)(39.7)(67.8)Operating EBITDA(21.9)(22.5)(44.4)(25.0)(37.8)(62.8)Depreciation &amp;amp; Amortisation(1.2)(1.0)(2.3)(1.5)(0.9)(2.4)Operating EBIT(23.2)(23.5)(46.7)(26.5)(38.7)(65.2)Other income0.00.00.00.00.000.0Net interest expense2.01.93.93.12.15.356.814.336.3Pre-tax profit(21.2)(21.5)(42.7)(22.4)(39.1)(61.4)Tax0.00.00.00.00.000.0Profit after tax(21.2)(21.5)(42.7)(22.4)(39.1)(61.4)Minorities0.00.00.00.00.000.0Normalised NPAT(21.2)(21.5)(42.7)(22.4)(39.1)(61.4)Non-recurring items0.00.00.00.00.000.0Reported profit(21.2)(21.5)(42.7)(22.4)(39.1)(61.4)Per shareNormalised EPS (cps)(1.8)(1.8)(3.6)(1.5)(2.7)(4.2)DPS (cps)0.00.00.00.00.000.0Average shares (mn)1,201.11,201.11,201.11,455.81,455.81,455.821.221.221.2Ratio analysis (%)Diff (bp)Diff (bp)Diff (bp)EBITDA marginnananananananaEBIT marginnananananananaEffective tax rate0.00.00.00.00.000.0000",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "7f98e43b4b4331bb",
      "text": "Source: Company data, Jefferies estimates",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "54ba0a5c660fe302",
      "text": "We make no changes to our IMM efti revenue forecasts. Changes to forecasts include:",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "0e727e51bd56ec6d",
      "text": "COGS: we have updated FY26E+ COGS in line with FY25 Other costs: we have updating other cost lines for FY26E+ in line with FY25 Net interest: This has been updated in line with period end balances",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4b6b4e3450f388fc",
      "text": "Our risk- weighted calculations of the near- term valuations in the IMM pipeline are shown below. We use these valuations of the IMM pipeline to calculate our price target. According to data from Tufts University, USA, the probability of success of clinical trials depends upon the stage of the clinical trial. This is seen in the following figure.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "c384130f871413b0",
      "text": "Figure 12 - Probability of drug getting onto market from a particular phase (%) (Tufts DiMasi data)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "568dcbc845142ba9",
      "text": "PhaseProbability of success of moving to the next phase (%)Probability of drug getting onto market from a particular phase (%)Phase 162.513.4Phase 235.021.4Phase 368.061.2",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "3ef04b6a0cebc346",
      "text": "Our risk-weighted valuation is shown below.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ca34bcc1113b9e89",
      "text": "Figure 13 -Immutep - Valuation Methodology",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "e93ff444c840a029",
      "text": "Valuation of IMM AU R&D portfolioRisk-weighted valuation (A$ per share)Risk Weighting (in line with clinical trial stage) (%)Total opportunity size (A$ per share)1st Line Met. Breast Ca AIPAC (Chemo/IQ)0.3621.41.671st line Met. Head &amp;amp; Neck Squamous Cell0.0821.40.391st line Non-Small-Cell Lung Cancer (IO-IQ)1.6861.22.74Total valuation (A$ rounded)2.10",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "b4c4d17f993b3271",
      "text": "Source: Jefferies estimates, Tufts data",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a36c7d043c72d62a",
      "text": "Figure 14-Immutep-Financial Summary (USSm)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "a1bc544e463f59e8",
      "text": "Figure 14 - Immutep - Financial Summary (US$m)Year-end 30 JuneFY24AFY25AFY26EFY27EFY28EValuation metrics Methodology: NPV of pipelineShare price (A$)0.25Income statement (A$m)DCF valuationTarget price (A$)2.10Total Revenue4544418DCF valuationUpside/Downside to TP757%Cost of goods sold0000(126)Rf (%)4.0Non-risk adj. DCF valuation (A$)4.81Gross profit4544292Rm-Rf (%)5.5R&amp;amp;D expenditure(31)(50)(65)(84)(109)Beta1.8Other expenses(17)(18)(21)(22)(23)Ke = (Rf + Beta(Rm-Rf))13.9(A$m)EBITDA(44)(63)(81)(102)160Equity (E/V)80.0NRW NPV of cash flow7,899Depreciation(0)(0)(0)(0)(4)Debt (D/V)20.0Add: Investments0Amortisation(2)(2)(2)(2)(3)Interest rate (Kd)6.5Less: Net debt-67EBIT(47)(65)(83)(104)153Tax rate (t)30.0Less: Minority0Net interest expense45223WACC12.0DCF Equity value7,966Earnings before tax(43)(61)(81)(102)155Multiples (x)FY24AFY25AFY26EFY28EIncome tax0000(47)FD normalised P/E(8.3)(5.8)(5.0)(5.1)Net profit after tax(43)(61)(81)(102)109FD normalised P/E/Grth0.4(0.3)(0.2)(1.1)Minority interests00000Reported P/E(8.3)(5.8)(5.0)(5.1)Normalised NPAT(43)(61)(81)(102)109Price/cashflow(10.2)(5.8)(5.1)(5.1)Significant items after tax00000Price/book1.92.53.64.3Reported NPAT(43)(61)(81)(102)109EV/EBITDA(4.4)(4.6)(4.6)(4.7)Shares (m)1,2011,4601,5621,8892,113EV/EBIT(4.2)(4.5)(4.5)(4.6)Per share (A$)EV/Sales50.857.686.6118.9Reported EPS(0.04)(0.04)(0.05)(0.05)0.05Dividend yield (%)0.00.00.00.0Fully diluted norm EPS(0.04)(0.04)(0.05)(0.05)0.05Multiples at target price (x)Book value per share0.160.100.070.060.11FD norm. P/E at price targetnanananaDPS0.000.000.000.000.01EV/EBITDA at price targetnanananaCashflow (A$m)Ratio analysis (%)FY24AFY25AFY26EFY28EYear-end 30 JuneFY24AFY25AFY26EFY27EFY28EGross margin100.0100.0100.0100.0EBITDA(44)(63)(81)(102)160EBITDA margin(1,156.1)(1,244.3)(1,882.0)(2,542.0)Change in working capital1(1)(1)(1)(2)EBIT margin(1,214.9)(1,291.7)(1,938.0)(2,598.0)Other operating cashflow8222(44)Net profit margin(1,111.7)(1,217.9)(1,884.2)(2,559.2)Cashflow from operations(35)(62)(80)(101)114Effective tax rate0.00.00.00.0Capital expenditure(0)(0)(0)(0)(4)Dividend payout0.00.00.00.0Free cashflow(35)(62)(80)(101)110Capex to sales0.80.96.06.0Net acquisitions(21)(38)000Capex to depreciation (x)0.10.21.01.0Cash dividends00000ROE(22.5)(42.8)(71.9)(85.1)Other investing cashflows0(0)000ROA (pretax)(117.3)(72.7)(89.9)(108.2)Cashflow after investing acts(56)(101)(80)(101)110Growth rate (%)Change in equity95(0)501100Sales RevenuenanananaChange in debt(0)(0)000EBITDA12.841.328.925.6Net cashflow39(101)(30)9110EBIT12.739.627.924.7Net debt/(cash)(161)(67)(35)(42)(149)Normalised NPAT7.143.831.926.3Balance sheet (A$m)Normalised FDEPs(20.4)18.722.94.5Year-end 30 JuneFY24AFY25AFY26EFY27EFY28ESegmental revenue (A$m)FY24AFY25AFY26EFY28ECash &amp; equivalents1626735421491st Line Net. Breact Ca AIPAC (Chemo/IO)000415Accounts receivable710131621New Ca Rx (Chemo - IO)0000Inventories00000Head &amp; Neck Squamous Cell Carcinoma (IO - IO)0000Other current assets2272727272New Ca Rx (IO - IO)0000Total current assets1911491201302421st line Non-Small-Cell Lung Cancer (IO-IO)0000LT investments00000Solid Tumours INSIGHT-004 (IO-IO)0000Fixed assets00000Total000415Goodwill00000Segmental EBIT (A$m)Other intangible assets877771st Line Net. Breact Ca AIPAC (Chemo/IO)000289Other LT assets21111New Ca Rx (Chemo - IO)0000Total assets202157128138250Head &amp; Neck Squamous Cell Carcinoma (IO - IO)0000Accounts payable1011131518New Ca Rx (IO - IO)0000Other current liabilities122221st line Non-Small-Cell Lung Cancer (IO-IO)000538Total current liabilities1013151721Solid Tumours INSIGHT-004 (IO-IO)0000Long-term debt10000Total000827Convertible debt00000Liquidity (x)Other LT liabilities11111Current ratio12123667Total liabilities1213151821Interest cover (EBIT)4100Minority interest00000LeverageCommon stock542545595705705Net debt/EBITDA (x)net cashnet cashnet cashnet cashRetained earnings(383)(444)(525)(627)(519)Net debt/equity (%)net cashnet cashnet cashnet cashOther equity and reserves3043434343Net debt/Net debt + equity (%)6986239711,337Total shareholders' equity19014411312022916Total equity &amp; liabilities202157128138250",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "902fce5df7dffaf5",
      "text": "Source: Company data, Jefferies estimates, Factset",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "0859c63833713818",
      "text": "Immutep Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in clinical trials as a chemoimmunotherapy combination for metastatic breast cancer. The company is in clinical trials for the treatment of head and neck squamous cell carcinoma (HNSCC) and non- small cell lung cancer. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T- cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T- cells involved in autoimmunity.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "c82084055cd9c4d1",
      "text": "In terms of valuation, there are three major potential commercial opportunities for IMM: 1) Breast cancer treatment; 2) Non- small Cell Lung Cancer treatment; and 3) head and neck squamous cell carcinoma treatment. We use our risk- weighted valuations of the IMM pipeline to calculate our price target.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "646cc66d423a459f",
      "text": "In terms of upside risks, IMM's product candidates use its technologies in the treatment of breast cancer as well as non- small- cell lung cancer and head and neck squamous cell carcinoma. Success in any of these clinical trials would lead to a positive re- rating of IMM's share price, in our view.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "fd279b2d46fa44e4",
      "text": "In terms of downside risks, there is still uncertainty around IMM's viability in most of its prospective markets. Pre- clinical trials, although positive, give no firm indication of a product's true viability, and future market conditions are unknown. To date, all preclinical and clinical trials have shown indications for the product's viability.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "dbfef47628f33081",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action or call 212.284.2300.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d92a7a0b1bf3c3f9",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "aa9a83f1feb30eb6",
      "text": "August 29, 2025 2:46 A.M. August 29, 2025 2:46 A.M.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "3155ccd292a4defd",
      "text": "With the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Immutep Ltd.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b888f790f4ea10b8",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from Inhibr, Inc. within the next three months.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "cf2394030e5ff30b",
      "text": "Within the past 12 months, Jefferies Financial Group Inc., its affiliates or subsidiaries has received compensation from investment banking services from Inhibr, Inc.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "d07940ffbb29a6af",
      "text": "Within the past twelve months, Jefferies Financial Group Inc. and/or its affiliates received compensation for products and services other than investment banking services from non- investment banking, securities related compensation for client services it provided to Inhibr, Inc.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "4f40c4de5f878f1f",
      "text": "Jefferies Financial Group Inc., its affiliates or subsidiaries has acted as a manager or co- manager in the underwriting or placement of securities for Inhibr, Inc. or one of its affiliates within the past twelve months.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "445be4070a63b063",
      "text": "For Important Disclosure information on companies recommended in this report, please visit our website at https://javatr.bluematrix.com/ sellside/Disclosures.action or call 212.284.2300.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "81c623fc8f75454d",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period. Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is plus or minus \\(20\\%\\) within a 12- month period. For Underperform rated securities with an average security price consistently below \\(10\\) , the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "ec87343676a4c6bb",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8d6d1658386ac627",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f404caf85faeca47",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "1d70361475689c05",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8951daf67dbf85ed",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "5b27a4f6df076a84",
      "text": "Jefferies methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "adeaf82db565bad8",
      "text": "Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a \\(15\\%\\) stop loss, and the remainder will have a \\(20\\%\\) stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "de60ef5249e9b31e",
      "text": "- Akseo Inc. (9926 HK: HK\\$152.20, BUY)- Bristol-Myers Squibb Co (BMY: \\$46.88, BUY)- Daiichi Sankyo (4568 JP: ¥3,534, BUY)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "08e6852d221b510a",
      "text": "- GSK Plc (GSK LN: p1,459.50, HOLD)- Immutep Ltd (IMM AU: AUD0.25, BUY)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d8b79fd920bafb36",
      "text": "Distribution of Ratings",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "9a815cf34eb960a7",
      "text": "CountPercentCountPercentCountPercentBUY211160.63%37017.53%1185.59%HOLD121334.84%1058.66%221.81%UNDERPERFORM1584.54%31.90%31.90%",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "74523a7e51311fee",
      "text": "Jefries does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies:",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "875ca569e662803c",
      "text": "United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "d45b9d8210df78ab",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "54ee46a693245364",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "f74cfa6a157c5d9f",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "941616362cdc6040",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "59b6388ead0344cd",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "baae3183e618f3e0",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "d729fd6eaca28415",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "7a5fe8406428ad94",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "2b8a80ff4120532c",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a \"permitted client\" as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "c1f54a7cbf87c057",
      "text": "whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "67ba9f89a804c477",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker- dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "a571b703fd101e27",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e681f7b581b60875",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "9d44f453d26baee8",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "fb360b50c4d166f4",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third- party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third- party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third- party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs,",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "74fdda1085d23a87",
      "text": "expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "65ac70d55550ca10",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "d5886a2639f53bd8",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 15,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "52fb904803289bc9",
      "name": "Akeso Bio",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cdd5fe8794670b85",
      "name": "Akseo Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cd36fa06d490a8bd",
      "name": "Antigen Presenting",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "146914ba3f2b493a",
      "name": "Australian Healthcare",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6dc1cabaeea74ba2",
      "name": "Be Still",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "90a0c1cb6b7a436e",
      "name": "Beach Boys",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "fd341d6c69c84c2e",
      "name": "Breact Ca",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "78351c46bc30f0cb",
      "name": "Breast Ca",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "582a2d84addf2c93",
      "name": "Brian Wilson",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f9e9481ee37fc228",
      "name": "Catalysts\n\nCatalystsIn",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0b51e8a80d6fdf0d",
      "name": "Cell Cancer",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e5de8e046c13857d",
      "name": "Cell Carcinoma",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0a1ce8f21ada8499",
      "name": "Cell Lung",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4e5ec4463f3892d3",
      "name": "Combined Positive",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0c759b57d9ad2ce6",
      "name": "Company Specific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a92ba89b9eff6c1b",
      "name": "Company Target",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2025E",
              "2026E",
              "2027E",
              "2028E",
              "2029E",
              "2030E"
            ]
          },
          "y": {
            "unit": "A$m",
            "range": {
              "min": 0,
              "max": 2000
            }
          }
        },
        "series": [
          {
            "name": "1st line Non-Small-Cell Lung Cancer (IO-IO)",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              0,
              900,
              1200
            ]
          },
          {
            "name": "1st line Met. Head & Neck Squamous Cell Carcinoma (IO-IO)",
            "unit": "A$m",
            "values": [
              0,
              0,
              0,
              400,
              500,
              600
            ]
          }
        ],
        "figure_id": "f42f9d440dd897a4",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "619a33a824a96aa1",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for. Immutep Ltd (IMM AU) as of 08-28-2025",
        "page": 13,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "AUD",
            "range": {
              "min": 0.2,
              "max": 0.5
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "AUD",
            "values": [
              0.28,
              0.32,
              0.25,
              0.35,
              0.28,
              0.32,
              0.4,
              0.48,
              0.42,
              0.3,
              0.25,
              0.35,
              0.3,
              0.25,
              0.28,
              0.22,
              0.28
            ]
          }
        ],
        "figure_id": "368cf2e2c7170bf0",
        "provenance": {
          "page": 13
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [
          {
            "name": "1st Line Non-Small-Cell Lung Cancer (IO-IO)",
            "unit": "%",
            "values": [
              79
            ]
          },
          {
            "name": "1st Line Met. Breast Ca APAC (Chemo/IO)",
            "unit": "%",
            "values": [
              null
            ]
          },
          {
            "name": "Met. Head & Squamous Cell (IO-IO)",
            "unit": "%",
            "values": [
              null
            ]
          }
        ],
        "figure_id": "90768b58f76a0392",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025",
              "+12 mo."
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 5
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": null,
            "values": [
              {
                "x": "2024",
                "y": 0.3
              },
              {
                "x": "2025",
                "y": 0.25
              },
              {
                "x": "+12 mo.",
                "y": 2.1
              }
            ]
          },
          {
            "name": "Upside",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 0.25
              },
              {
                "x": "+12 mo.",
                "y": 4.81
              }
            ]
          },
          {
            "name": "Downside",
            "unit": null,
            "values": [
              {
                "x": "2025",
                "y": 0.25
              },
              {
                "x": "+12 mo.",
                "y": 0.05
              }
            ]
          }
        ],
        "figure_id": "fd70eb827f1ea894",
        "provenance": {
          "page": 2
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "71eadc59f7e8f1e0",
        "value": -0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "CLC. We believe IMM has as its primary target market patients with a low Tumor Proportion Score of 1-49%, c37% of the total advanced NSCLC market. **Efti/pembro has the highest median Overall Survival",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "523965ece57b2788",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "believe IMM has as its primary target market patients with a low Tumor Proportion Score of 1-49%, c37% of the total advanced NSCLC market. **Efti/pembro has the highest median Overall Survival (mOS) w",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "249df3b485322890",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "could treat 1L HNSCC patients with a Combined Positive Score &lt;1 under a new treatment regimen, c20% of the total 1L HNSCC market. ![Figure 0-2](images/0_2.jpg) **Also, efti/pembro has the highest m",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "6b1424e650976849",
        "value": 7.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "BUY</td></tr><tr><td>PRICE</td><td>AUD0.25*</td></tr><tr><td>PRICE TARGET | % TO PT</td><td>AUD2.10|+757%</td></tr><tr><td>52W HIGH-LOW</td><td>AUD0.42-AUD0.22</td></tr><tr><td>FLOAT (%)| ADV MM (USD)",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "44167e7d87f86a3a",
        "value": 0.853,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>52W HIGH-LOW</td><td>AUD0.42-AUD0.22</td></tr><tr><td>FLOAT (%)| ADV MM (USD)</td><td>85.3%|0.62</td></tr><tr><td>MARKET CAP</td><td>AUD407.8M|&#36;266.1M</td></tr><tr><td>TICKER</td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5084e10623d0c321",
        "value": 7.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "![Figure 1-0](images/1_0.jpg) <center>Risk/Reward - 12 Month View </center> ## Base Case, AUD2.1,+757% Base Case, AUD2.1, +757%Our base case price target uses our risk- weighted valuations for the nea",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "b21aa4959b933ed4",
        "value": 7.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "jpg) <center>Risk/Reward - 12 Month View </center> ## Base Case, AUD2.1,+757% Base Case, AUD2.1, +757%Our base case price target uses our risk- weighted valuations for the near- term valuations in the",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f7ba45902cd3d87b",
        "value": 8.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Cancer; and 3) Treatment of Head and Neck Squamous Cell Carcinoma. ## Upside Scenario, AUD4.81,+1,863% Upside Scenario, AUD4.81, +1,863%Our upside case price target is a non- risk weighted valuation f",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "4353a574fbb5078d",
        "value": 8.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nd Neck Squamous Cell Carcinoma. ## Upside Scenario, AUD4.81,+1,863% Upside Scenario, AUD4.81, +1,863%Our upside case price target is a non- risk weighted valuation for our valuation of IMM's base- ca",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "09bd96a8ae00d23c",
        "value": -0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ghted valuation for our valuation of IMM's base- case opportunities. ## Downside Scenario, AUD0.05,-80% Downside Scenario, AUD0.05,- 80%Our downside case assumes all clinical trials fail. Hence, the s",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "455c9a76d9c06ec2",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f IMM's base- case opportunities. ## Downside Scenario, AUD0.05,-80% Downside Scenario, AUD0.05,- 80%Our downside case assumes all clinical trials fail. Hence, the stock would likely trade at its cash",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d0bda47c424cd877",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "believe IMM has as its primary target market patients with a low Tumor Proportion Score (TPS) of 1- 49% (a 'cold' tumour), c37% of the total 1L NSCLC market. The Tumor Proportion Score in non- small c",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "878dc7e39bf42d70",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rimary target market patients with a low Tumor Proportion Score (TPS) of 1- 49% (a 'cold' tumour), c37% of the total 1L NSCLC market. The Tumor Proportion Score in non- small cell lung cancer is defin",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e5a04d9db504c1d8",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "to all viable tumor cells present in the sample. The TPS is expressed as a percentage, ranging from 0% (no tumor cells stained) to 100% (all tumor cells stained). We note: - Competing drugs that saw c",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bb971871c1e05dc9",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nt in the sample. The TPS is expressed as a percentage, ranging from 0% (no tumor cells stained) to 100% (all tumor cells stained). We note: - Competing drugs that saw comparable ORR to eftilagimod in",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a1bc664aae3054a2",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "at saw comparable ORR to eftilagimod in IMM's TACTI-002 trial are only recruiting patients with TPS>50%, and so are not targeting the same primary market as eftilagimod and pembrolizumab, which is lik",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8d6597cba5bdec79",
        "value": -0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e not targeting the same primary market as eftilagimod and pembrolizumab, which is likely to be TPS1-49%. These competing trials are TROPION-Lung08, MK-3475-D46 and MK-2870-007.- The Objective Respons",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "cb2dc8f026e60041",
        "value": -0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "K-2870-007.- The Objective Response Rate (ORR) is highest for pembrolizumab and eftilagimod in TPS 1-49% in early stage trials when compared to peers. That said, these trials are likely to read out Ph",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2c1f9e64ad5de281",
        "value": -0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "l will be stratified, with distinct results (and p values) to be generated for patients in the TPS 1-49% subgroup, as well as the TPS>50% subgroup. Figure 7 - Efti/Keytruda combination and monotherapy",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "524c230b5caefe17",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t results (and p values) to be generated for patients in the TPS 1-49% subgroup, as well as the TPS>50% subgroup. Figure 7 - Efti/Keytruda combination and monotherapy vs. other agents being developed ",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9f8102d38527aa9a",
        "value": 0.63,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Randomized</td><td>500</td><td>Recruiting</td><td>Merus NV</td><td>Jan-28</td><td>1L: Overall ORR: 63%, ORR in CPS&amp;lt;1: na, ORR in CPS 1-19: 47%, ORR in CPS&amp;gt;20: 73%. mPFS 9 months</td></t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "41feb9abe9c1da41",
        "value": 0.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Merus NV</td><td>Jan-28</td><td>1L: Overall ORR: 63%, ORR in CPS&amp;lt;1: na, ORR in CPS 1-19: 47%, ORR in CPS&amp;gt;20: 73%. mPFS 9 months</td></tr><tr><td>2</td><td>Zanzalintinib (STELLAR-305)",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "2b36ca055dab9466",
        "value": 0.73,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1L: Overall ORR: 63%, ORR in CPS&amp;lt;1: na, ORR in CPS 1-19: 47%, ORR in CPS&amp;gt;20: 73%. mPFS 9 months</td></tr><tr><td>2</td><td>Zanzalintinib (STELLAR-305)</td><td>2&amp;amp;3</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "4443e2093fb6a474",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ting</td><td>Exelixis</td><td>Aug-28</td><td>Recruiting in 1L for CPS ≥1. Previous 2L: Overall ORR: 54%, Median OS in CPS&amp;lt;20: 15 months, median OS in CPS&amp;gt;20: 33 months. Overall PFS: 14.6",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "5485e7550293e551",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Randomized</td><td>410</td><td>Recruiting</td><td>Inhibix</td><td>May-29</td><td>1L: Overall ORR: 30%. 1L: ORR in CPS&amp;lt;1: 36% (mOS 17.6m), ORR in CPS 1-19: 35%, ORR in CPS&amp;gt;20: 31%, ORR ",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "da12a55430a45efe",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Recruiting</td><td>Inhibix</td><td>May-29</td><td>1L: Overall ORR: 30%. 1L: ORR in CPS&amp;lt;1: 36% (mOS 17.6m), ORR in CPS 1-19: 35%, ORR in CPS&amp;gt;20: 31%, ORR in CPS&amp;gt;1: 33%.</td></tr",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e276a0f48313d1ab",
        "value": 0.35,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>May-29</td><td>1L: Overall ORR: 30%. 1L: ORR in CPS&amp;lt;1: 36% (mOS 17.6m), ORR in CPS 1-19: 35%, ORR in CPS&amp;gt;20: 31%, ORR in CPS&amp;gt;1: 33%.</td></tr><tr><td>4</td><td>Eftaligimod (TA",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "01c27f81f2594780",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "all ORR: 30%. 1L: ORR in CPS&amp;lt;1: 36% (mOS 17.6m), ORR in CPS 1-19: 35%, ORR in CPS&amp;gt;20: 31%, ORR in CPS&amp;gt;1: 33%.</td></tr><tr><td>4</td><td>Eftaligimod (TACTI-003)</td><td>2B</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6c48ab2dc5a66a0c",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "PS&amp;lt;1: 36% (mOS 17.6m), ORR in CPS 1-19: 35%, ORR in CPS&amp;gt;20: 31%, ORR in CPS&amp;gt;1: 33%.</td></tr><tr><td>4</td><td>Eftaligimod (TACTI-003)</td><td>2B</td><td>Open Label, Randomized</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "04dfb9c7af134226",
        "value": 0.162,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "cruiting</td><td>National Cancer Institute</td><td>Jul-25</td><td>2L: Overall ORR in CPS&amp;gt;25: 16.2%. Median OS in CPS&amp;gt;25: 7.1 months</td></tr><tr><td>6</td><td>Danvatrisen</td><td>2</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "39b0376d994ddd34",
        "value": 0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ecruiting</td><td>Washington University Apr-31 School of Medicine</td><td></td><td>1L: Overall ORR: 64%, ORR in CPS&amp;lt;20: 64%, ORR in CPS&amp;gt;20: 60%. Overall PFS: 2.1 months</td></tr></table>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e51753140fed7aec",
        "value": 0.64,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n University Apr-31 School of Medicine</td><td></td><td>1L: Overall ORR: 64%, ORR in CPS&amp;lt;20: 64%, ORR in CPS&amp;gt;20: 60%. Overall PFS: 2.1 months</td></tr></table> Source: clinicaltrials.gov",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0dfad9964cbdbb81",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "of Medicine</td><td></td><td>1L: Overall ORR: 64%, ORR in CPS&amp;lt;20: 64%, ORR in CPS&amp;gt;20: 60%. Overall PFS: 2.1 months</td></tr></table> Source: clinicaltrials.gov, company data ## B. Eftali",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c40beeec5eb4f3a5",
        "value": 0.36,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pen Label, Randomized</td><td>31</td><td>Completed</td><td>Immutep</td><td>1L: ORR in CPS&amp;lt;1: 36%</td><td>17.6</td></tr><tr><td>pembrolizumab monotherapy (KN-048) cetuximab + chemotherapy (KN-04",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "084fcc3006f759e5",
        "value": 0.045,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Open Label / Randomized</td><td>43</td><td>Completed</td><td>Merck</td><td>1L: ORR in CPS&amp;lt;1: 4.5%</td><td>7.9</td></tr><tr><td>pembrolizumab + chemotherapy (KN-048)</td><td>CPS&amp;lt;1</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "23d9eb41b59f3ccc",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Open Label / Randomized</td><td>43</td><td>Completed</td><td>Merck</td><td>1L: ORR in CPS&amp;lt;1: 31%</td><td>10.7</td></tr><tr><td>lvosencimab monotherapy (AK117-201)</td><td>CPS&amp;gt;1</td><td>2",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "46d7c0e423e2aed6",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "domized</td><td>10</td><td>Active, not completed</td><td>Akeso Bio</td><td>1L: ORR in CPS&amp;lt;1: 40%</td><td>11.3</td></tr><tr><td>lvosencimab plus ligufalimab (AK117-201)</td><td>CPS&amp;gt;1</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "3cb8e72ea3fa430e",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mized</td><td>20</td><td>Active, not completed</td><td>Akeso Bio</td><td>1L: ORR in CPS&amp;gt;1 is 30%. mPFS is 5.0m</td><td>na</td></tr></table> Source: Company data, PubMed We note that in the more",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "67ea042df0ee8b98",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>29.5</td></tr><tr><td>1L NSCLC as a percentage of total volume of use of Keytruda</td><td>40%</td></tr><tr><td>Within 1L NSCLC, TPS 1-49% as a percentage of total Ca</td><td>37%</td></tr><tr",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "5bbac88888d21f63",
        "value": -0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "a percentage of total volume of use of Keytruda</td><td>40%</td></tr><tr><td>Within 1L NSCLC, TPS 1-49% as a percentage of total Ca</td><td>37%</td></tr><tr><td>Hence, revenue protected per annum for ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "165879a5cc98531e",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "eytruda</td><td>40%</td></tr><tr><td>Within 1L NSCLC, TPS 1-49% as a percentage of total Ca</td><td>37%</td></tr><tr><td>Hence, revenue protected per annum for Keytruda from combo. Rx with Efti</td><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "42589a1a6d02137c",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ti</td><td>4.4</td></tr><tr><td>1L HNSCC as a percentage of total volume of use of Keytruda</td><td>10%</td></tr><tr><td>Within HNSCC, CPS &amp;lt;1 as a percentage of total Ca</td><td>20%</td></tr><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "19b54abc5b340fda",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ytruda</td><td>10%</td></tr><tr><td>Within HNSCC, CPS &amp;lt;1 as a percentage of total Ca</td><td>20%</td></tr><tr><td>Hence, revenue protected per annum for Keytruda from combo. Rx with Efti</td><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "69440379f85217c6",
        "value": 29500000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "per annum for pembrolizumab from combination therapy with eftilagimod We note pembrolizumab's (US\\$29.5Bn in FY24 revenue) patent ends in 2028. IMM previously stated eftilagimod plus pembrolizumab cou",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "57dd6fd59aec4f9c",
        "value": 5000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "revenue protected per annum for pembrolizumab from combination therapy with eftilagimod could be US\\$5.0Bn, should this combination be successful. Figure 10 - Calculating annual revenue protected for ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "60fd805130d46f87",
        "value": 7.57,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>5</td><td>4</td><td>4</td><td>418</td><td>DCF valuation</td><td>Upside/Downside to TP</td><td>757%</td><td></td></tr><tr><td>Cost of goods sold</td><td>0</td><td>0</td><td>0</td><td>0</td><td>(1",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ecc40633d8c5f312",
        "value": 152.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "le such as growth or value. ## Other Companies Mentioned in This Report - Akseo Inc. (9926 HK: HK\\$152.20, BUY)- Bristol-Myers Squibb Co (BMY: \\$46.88, BUY)- Daiichi Sankyo (4568 JP: ¥3,534, BUY)<｜end",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "91b164245293b512",
        "value": 46.88,
        "unit": "$",
        "metric_type": "currency",
        "context": "s Mentioned in This Report - Akseo Inc. (9926 HK: HK\\$152.20, BUY)- Bristol-Myers Squibb Co (BMY: \\$46.88, BUY)- Daiichi Sankyo (4568 JP: ¥3,534, BUY)<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "15dc0ad106bdc2f9",
        "value": 3534.0,
        "unit": "¥",
        "metric_type": "currency",
        "context": ". (9926 HK: HK\\$152.20, BUY)- Bristol-Myers Squibb Co (BMY: \\$46.88, BUY)- Daiichi Sankyo (4568 JP: ¥3,534, BUY)<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "ae71c52a79184b67",
        "value": 0.6063000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "5ec67bb19880525f",
        "value": 0.1753,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "8ffdd747f3a78830",
        "value": 0.0559,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2111</td><td>60.63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "6f27b02772f32f50",
        "value": 0.34840000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "63%</td><td>370</td><td>17.53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158<",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "066a2332f0aa6d04",
        "value": 0.0866,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "53%</td><td>118</td><td>5.59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "38c4fb44cc72853e",
        "value": 0.0181,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".59%</td></tr><tr><td>HOLD</td><td>1213</td><td>34.84%</td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td>",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "b8cbc0e100674de2",
        "value": 0.0454,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.66%</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "c9a10a4c917a3178",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.81%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "289af05337439f93",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>158</td><td>4.54%</td><td>3</td><td>1.90%</td><td>3</td><td>1.90%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 12
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 5,
      "tables_count": 0,
      "numerical_data_count": 58,
      "passages_count": 134,
      "entities_count": 20
    }
  }
}